“Carcinoma de pulmón célula no pequeña: ¿hay diferencias por histología utilizando inmunoterapia?” - page 2

Nivolumab PR

Docetaxel

73 y.o man

Squamous cell carcinoma

T4N2M1

ECOG PS 1

Carboplatin + paclitaxel

July 2012

January 2013

July 2013

Introduction

What factors may

impact outcomes with immune checkpoint

inhibitors?

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1 3,4,5,6,7,8,9,10,11,12,...21